Recombinant Human LILRA6/CD85b/ILT8 Protein, CF

When Recombinant Human LILRA6/CD85b/ILT8 is coated onto a microplate at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7 (Catalog #914-AN) binds with a typical ED50 of0.1-0.6 µg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LILRA6/CD85b/ILT8 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LILRA6/CD85b/ILT8 is coated onto a microplate at 2 μg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with a typical ED₅₀ = 0.1-0.6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human LILRA6/CD85b protein
  Gly24-Asn447, with a C-terminal 6-His tag
• Accession #: Q6PI73
• N-terminal Sequence: Gly24
• Protein/Peptide Type: Recombinant Proteins
• Gene: LILRA6
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-69 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LILRA6/CD85b/ILT8 Protein, CF

• 7M1
• CD85b
• CD85b;ILT5;ILT8;ILT-8;LILRB3;LILRB6
• ILT8
• LILRA6
• Pira3

Background

LILRA6, also known as ILT8 and CD85b, is a transmembrane molecule that belongs to the LILR family of immune regulatory proteins (1, 2). Among family members, LILRA6 is most closely related to LILRB3/CD85a/ILT5; these proteins share 94% amino acid (aa) sequence identity in their extracellular domains (ECD). Mature human LILRA6 consists of a 424 aa ECD with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 13 aa cytoplasmic domain (3). It contains a positively charged arginine residue in the transmembrane segment which may mediate association with the signaling protein Fc epsilon  RI gamma. Alternative splicing generates a short isoform that is truncated near the middle of the ECD. LILRA6 is highly polymorphic, and its gene is found in variably copy numbers (4, 5). LILRA6 is primarily expressed on monocytes (4). R&D Systems in-house testing indicates that LILRA6 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families (6).

1. Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
2. Hirayasu, K. and H. Arase (2015) J. Hum. Genet. 60:703.
3. Wende, H. et al. (2000) Immunogenetics 51:703.
4. Bashirova, A.A. et al. (2014) Immunogenetics 66:1.
5. Lopez-Alvarez, M.R. et al. (2014) Immunogenetics 66:73.
6. Zheng, J. et al. (2012) Nature 485:656.

Bioinformatics

• Gene Symbol: LILRA6
• Uniprot:
  • Q6PI73()